ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD: Case 1 - Episode 7
What are the expectations of therapy in this setting?
The therapy choice that I would make is exemestane and everolimus, and I think that when compared to the standard of care which existed before everolimus, exemestane alone had about a 4-month progression-free survival. When exemestane and everolimus were given together, that progression free survival went up to about 9 months. In fact, if you look at some of the data from the clinical trials, the independently reviewed data, it's probably about 10 months.
ER+/HER2-Breast Cancer: Case 1
Angela is a 56-year-old woman, who in 2013 was diagnosed with a 4 cm IDC of the left breast, ER positive at 50%, PR negative, and Her2 negative. She was treated with four cycles of neoadjuvant doxorubicin and cyclophosphamide, followed by twelve weeks of paclitaxel.
She then had a left MRM with AD, showing a residual 1.5 cm tumor with 3/10 LN positive
She received anastrozole, and in early 2015 she complained of low back pain and a bone scan revealed multiple areas of uptake in the lumbosacral spine
PET-CT revealed lytic lesions in the lumbosacral spine and pelvis, and a 2 cm low attenuation lesion in the liver with a PET SUV value of 10, indicating malignancy
She was placed on denosumab 120 mg SQ monthly, and fulvestrant 500 mg IM monthly. Her pain resolved within 2 months, and on follow-up CT qt 4 months her bone lesions appeared sclerotic and her liver lesion had reduced to 1 cm. Her fulvestrant and denosumab were continued.
In early 2016 she again complained of worsening low back pain and left hip pain
Repeat PET-CT demonstrated new lytic lesions in the left iliac crest as well as an enlargement of the liver lesion to 3 cm